Baxter Intl Inc Stock Price, News & Analysis

The ExactaMix Pro Automated Compounder from Baxter International (NYSE:BAX), set for release in early 2023, enhances security and user experience while offering superior data reporting capabilities. It will be showcased at the ASHP Midyear Clinical Meeting from Dec. 4-8, 2022. This advanced system is certified to the FDA-recognized UL 2900-2-1 cybersecurity standard and provides features designed for increased efficiency and ease of use, including touchscreen responsiveness and 15 months of data storage. ExactaMix Pro signals a significant advancement in compounding technology.

Baxter International Inc. (NYSE:BAX) will participate in the 5th Annual Evercore ISI HealthCONx Conference on December 1, 2022, at 1:00 p.m. Eastern Time. Chief Financial Officer Jay Saccaro will present at the event. A live webcast will be available on www.baxter.com and can be replayed until May 30, 2023. With a legacy of 90 years, Baxter continues to innovate in areas like diagnostic and critical care solutions across over 100 countries, helping millions of patients and caregivers globally.

Baxter International Inc. (NYSE:BAX) has declared a quarterly cash dividend of $0.29 per share, payable on January 3, 2023. Shareholders of record by December 2, 2022 will receive this dividend. The annual dividend rate is set at $1.16 per share. Baxter continues to maintain its commitment to returning value to shareholders while focusing on innovations in healthcare.

Baxter International Inc. (NYSE:BAX) presented significant data at Kidney Week 2022 demonstrating the benefits of its remote patient management platform, Sharesource, and the Theranova dialyzer. A controlled study revealed that Sharesource improves outcomes for home peritoneal dialysis patients by reducing adverse events. Additionally, ex vivo studies indicated that Theranova effectively removes larger middle-molecule toxins while maintaining albumin stability during hemodialysis. These innovations aim to enhance patient care in response to the global kidney disease crisis.

Baxter International reported third-quarter 2022 revenue of $3.8 billion, a 17% increase on a reported basis. U.S. GAAP EPS was ($5.83), reflecting $3.1 billion in impairment charges from the Hillrom acquisition, attributed to rising interest rates and equity declines. Adjusted EPS was $0.82, a 20% decrease year-over-year. International sales grew 1%, while U.S. sales surged 40%. Despite challenges from supply constraints and competition, Baxter's product innovations continue to drive growth. The company anticipates 17%-18% sales growth for the full year.

Baxter International Inc. (NYSE:BAX) will host a conference call on October 27, 2022, at 7:30 a.m. Central Time to discuss its third-quarter financial results. Interested participants can pre-register for the call via the provided link. The call will also be webcasted through Baxter’s official website, where it will be accessible after the live session. Baxter provides critical healthcare products across multiple sectors, serving patients globally. For more information, visit www.baxter.com.

Baxter International Inc. (NYSE:BAX) has announced a commitment of $400,000 to create scholarships aimed at increasing diversity in healthcare professions. This includes the establishment of the Baxter Nursing Scholars Award at Tennessee State University's School of Nursing and the Baxter Healthcare Scholarship at Howard University College of Pharmacy. The initiative is part of Baxter's Activating Change Today initiative to advance racial justice and support underrepresented Black students in health and sciences.

Baxter International (NYSE:BAX) has received FDA 510(k) clearance for its new Novum IQ syringe infusion pump, which features Dose IQ Safety Software. This advancement aims to enhance medication delivery safety, specifically for neonatal and pediatric patients. The Novum IQ SYR integrates seamlessly with hospital electronic medical records (EMRs) and incorporates advanced safety measures, including drug library access and titration error prevention. Baxter's IQ Enterprise Connectivity Suite allows for real-time infusion data and operating system upgrades, optimizing hospital resources.

Baxter International Inc. (NYSE:BAX) will present at the 2022 Wells Fargo Healthcare Conference on September 7, 2022, at 10:25 a.m. Eastern Time. CFO Jay Saccaro is scheduled to discuss the company’s innovations and healthcare solutions. A live webcast of the presentation can be accessed at www.baxter.com and will be available for replay until February 23, 2023. Baxter has a 90-year history of providing critical healthcare products and services globally, impacting millions of patients and caregivers.